Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis

Julien Edeline*, Angela Lamarca, Mairéad G McNamara, Timothy Jacobs, Richard A Hubner, Dan Palmer, Bas Groot Koerkamp, Philip Johnson, Boris Guiu, Juan W Valle

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)
2 Downloads (Pure)

Abstract

BACKGROUND: Locoregional treatments (LRT) including radioembolisation (SIRT), transarterial chemo-embolisation (TACE), hepatic arterial infusion (HAI) of chemotherapy, external beam radiotherapy (EBRT) and ablation have been studied for the management of intrahepatic cholangiocarcinoma (iCC). The aim of this systematic review was to provide outcome benchmarks for clinical trial design.

METHODS: Identification of studies reporting outcomes of patients treated with LRT for iCC was performed using PubMed and Embase. Pooled weighted means were calculated for progression-free survival (PFS) and overall survival (OS); meta-analysis of proportions was used for estimation of pooled response rate.

RESULTS: 6325 entries were reviewed; 93 studies were eligible, representing 101 cohorts and 3990 patients: 15 cohorts (645 patients) for ablation, 18 cohorts (541 patients) for EBRT, 27 cohorts (1232 patients) for SIRT, 22 cohorts (1145 patients) for TACE, 16 cohorts (331 patients) for HAI and 3 cohorts (96 patients) not pooled. 74% of the studies were retrospective, 99% non-randomised. The pooled mean weighted OS was 30.2 months (95% confidence interval (CI): 21.8-38.6) for ablation, 18.9 (14.2-23.5) for EBRT, 14.1 (12.1-16.0) for SIRT, 15.9 (12.9-19.0) for TACE and 21.3 (15.4-27.1) for HAI. The pooled complete response rate was 93.9% for ablation. When analysed together, SIRT, TACE and HAI had a pooled mean weighted OS of 15.7 months, and 25.2 months for patients treated in first-line with concomitant systemic chemotherapy.

CONCLUSIONS: Available literature on LRT for iCC was heterogeneous and of insufficient quality to make strong recommendations. Ablation achieved satisfactory outcomes, and may be recommended when surgery is not feasible.

Original languageEnglish
Article number102258
JournalCancer Treatment Reviews
Volume99
DOIs
Publication statusPublished - 1 Sep 2021

Bibliographical note

Financial support:
This publication is based upon work of COST Action CA18122 – European Cholangiocarcinoma Network; supported by COST (European
Cooperation in Science and Technology; www.cost.eu), a funding agency for research and innovation networks.
Dr Angela Lamarca received funding from The Christie Charity and the European Union’s Horizon 2020 Research and Innovation Programme [grant number 825510, ESCALON]; she is a member of the CA18122 COST Action.

Copyright © 2021. Published by Elsevier Ltd.

Fingerprint

Dive into the research topics of 'Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis'. Together they form a unique fingerprint.

Cite this